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Abstract
Background: Pulmonary hypertension (PH) associated with lung disease has the worst prognosis of all types of PH.
Pulmonary arterial vasculopathy is an early event in the natural history of chronic obstructive pulmonary disease
(COPD) and interstitial lung disease (ILD). The present study characterized the alterations in the structure and
function of the pulmonary arterial (PA) wall of COPD and ILD candidates for lung transplantation (LTx).
Methods: A cohort of 73 patients, 63 pre-LTx (30 COPD, 33 ILD), and ten controls underwent simultaneous right
heart catheterisation and intravascular ultrasound (IVUS). Total pulmonary resistance (TPR), capacitance (Cp), and the
TPR-Cp relationship were assessed. PA stiffness and the relative area of wall thickness were estimated as pulse PA
pressure/IVUS pulsatility and as [(external sectional area-intimal area)/external sectional area] × 100, respectively.
Results: Twenty-seven percent of patients had pulmonary arterial wedge pressure > 15 mmHg and were not analyzed.
PA stiffness and the area of wall thickness were increased in comparison with controls, even in patients without PH
(p < 0.05). ILD patients showed a significant higher PA stiffness, and lower Cp beyond mean PA pressure (mPAP)
and lower area of wall thickness than COPD patients (p < 0.05). TPR-Cp relationship was shifted downward left for
ILD patients.
Conclusions: Significant increase of PA stiffness and area of wall thickness were present even in patients without
PH and can make the diagnosis of pulmonary vasculopathy at a preclinical stage in PH-lung disease candidates
for LTx. ILD patients showed the worst PA stiffness and Cp with respect to COPD.
Keywords: Pulmonary hypertension, Lung transplantation, Pulmonary arterial wall, Chronic obstructive pulmonary
disease, Interstitial lung disease
Background
Pulmonary hypertension (PH) is a well-recognized com-
plication of chronic obstructive pulmonary disease
(COPD) and interstitial lung disease (ILD) that impacts
on the functional capacity, the risk of hospitalization,
and survival [1]. PH associated with lung disease has the
worst prognosis of all types of PH [2]. The prevalence of
PH in both chronic lung diseases depends on the sever-
ity of the disease and the definition and methodologies
used in the studies [3, 4]. Most of the available data
regarding PH-lung disease comes from patients under-
going evaluation for lung transplantation (LTx). In a
recent cohort of 362 patients with severe COPD who
were evaluated for LTx and underwent right heart
catheterization, the prevalence of pre-capillary PH was
23% [5, 6]. PH may complicate the course of many forms
of ILD [7, 8]. The prevalence of PH for idiopathic pul-
monary fibrosis (IPF), the most frequent of ILD disease,
is between 10 to 80% [9–11].
The relation between the severity and extent of pul-
monary vascular disease and the degree of hemodynamic
abnormalities seen in PH-lung disease is poorly under-
stood [1]. Recently, the analysis of pulmonary arterial
lesions in explanted lungs of COPD patients demon-
strated that histological pulmonary vascular changes are
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prevalent, including lesions Grade 3 (Heath & Edwards)
even in patients without PH [12]. The analysis of the
United Network for Organ Sharing database showed that
an increase in the mean pulmonary arterial pressure
(mPAP) from the time of wait listing to the time of LTx
was associated with poorer survival in patients with
COPD and ILD after LTx even in the lung allocation
scoring era [6, 13]. Therefore, the early diagnosis of pul-
monary vascular disease and PH in COPD and ILD can-
didates for LTx could have an impact on survival.
We hypothesized that pulmonary vascular disease is
present even with normal resting mPAP and would be
related to the hemodynamic and parenchymal disease
severity (obstructive/restrictive impairment) in COPD
and ILD candidates for LTx. The first aim of the present
study is to assess and to compare the extent of func-
tional (pulmonary artery stiffness, PAS) and anatomical
(area of wall thickness, AWT) pulmonary vascular
disease in COPD and ILD candidates for LTx according
to the hemodynamic severity. The second aim was to
correlate the pulmonary arterial vasculopathy with the
severity of airway and parenchymal lung impairment in
COPD and ILD candidates for LTx, respectively.
Methods
Study design
A cohort of 63 consecutive adult subjects candidates
for LTx for COPD (n = 30) and ILD (n = 33) between
January 2011 and December 2012 was included. All
patients were studied as potential candidates for lung
transplantation according to the International Society
for Heart and Lung Transplantation guidelines [14].
Evaluation included clinical and laboratory examin-
ation, chest X-ray imaging, pulmonary function tests
(forced expiratory volume in one second, FEV1; the
forced vital capacity, FVC; diffusion capacity for carbon
monoxide, DLCO), electrocardiography, 6-min walk
test (6MWT), Doppler echocardiography, and high-
resolution computed tomography imaging. All patients
underwent a routine right heart catheterization and
simultaneous medium-sized elastic pulmonary arteries
intravascular ultrasound (IVUS) in the supine position
and breathing room air.
The patients were compared with ten control subjects
referred for cardiac catheterization due to clinically sus-
pected PH, and in whom PH and other respiratory and
cardiovascular diseases were discarded. PH was defined
as mPAP greater or equal than 25 mmHg.
The study complied with the Declaration of Helsinki
and the study protocol was approved by the Institutional
Ethics Committee of the Hospital Universitari Vall
d’Hebron (Barcelona). Written informed consent was
obtained from all patients.
Hemodynamic and IVUS studies
A 7 F Swan-Ganz catheter was inserted into a brachial
vein, and a 5 F end-hole catheter was inserted into the
right radial artery to monitor systemic arterial pressure.
Both catheters were connected to pressure transducers.
The zero reference level for recording was at mid-
thoracic level [15]. An electrocardiogram and heart rate
were recorded continuously, and cardiac output (CO)
was assessed using the indirect Fick method. Resting
oxygen uptake was calculated by the formula of Dehmer,
based on body surface area (BSA) (125 mL/min/m2 ×
BSA) [16]. All pressures, including right atrial pressure
(RAP), mPAP and pulmonary arterial wedge pressure
(PAWP), were taken in the supine position and at end-
expiration [17]. We calculated pulmonary vascular
resistance (PVR) and total pulmonary resistance (TPR)
as (mPAP-PAWP)/CO and mPAP/CO, respectively.
Total pulmonary arterial capacitance (Cp) was estimated
by the stroke volume/pulse PAP ratio [18]. We discarded
the patients with PAWP ≥ 15 mmHg. We estimated pul-
monary arterial RC time as the product of resistance and
capacitance (PVR × Cp). We examined the relationship
between TPR and Cp to analyze the consequences of
pulmonary vascular disease to the dynamic afterload
[19]. To compare the TPR-Cp relationship for each
group, the TPR, and Cp data were logarithmically trans-
formed and plotted on a linear axis.
IVUS examination was performed with an Opticross
imaging catheter 40 MHz, 3.1 F (Boston Scientific
Corporation, USA) with an axial resolution of 38 μm. A
minimum of three representative images were obtained
from segmental pulmonary arteries (elastic pulmonary
artery ~ 2–3 mm of diameter) [20, 21] and stored in
digital form. Both diastolic and systolic cross-sectional
areas of the studied segment were analyzed off-line by
two observers unaware of clinical and hemodynamic find-
ings. We estimated IVUS pulsatility (IVUSp) as (systolic-
diastolic lumen area)/diastolic lumen area × 100. PAS was
assessed by the elastic modulus (EM) or pressure/elastic
strain index (pulse PAP/IVUSp), an expression of the
intrinsic pulmonary arterial wall viscoelastic properties [22].
Intra- and inter-observer validation of IVUS measurements
in our laboratory have been previously published [20, 21].
Because of the strong dependency of strain on under-
lying pressures, we compared Cp and EM of both
groups according to mPAP [22]. Finally, we calculated
the relative AWT as (external sectional area-intimal
area)/external cross-sectional area × 100 [23].
Statistical analysis
Continuous variables are expressed as mean ± SEM. Cat-
egorical variables were summarized by frequency. Inde-
pendent sample t-tests were used to compare differences
between the control, COPD and ILD patients. Chi-squared
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was used for comparing proportions of patients. Intergroup
variation was analyzed using one-way ANOVA.
The association between vascular remodeling (EM and
AWT), hemodynamic impairment and lung functional
tests were explored using linear regression analysis
(Pearson coefficient). A two-sided P value < 0.05 was
regarded as significant. Data analysis were carried out
using SPSS 17.0 for Windows 7 software.
Results
Twenty-seven percent of patients had PAWP > 15 mmHg
(n = 17) and were excluded. Pre-capillary PH was pre-
sented in 44% of COPD (8/18) and 46% of ILD (13/28).
COPD and ILD patients presented an unimodal distribution
with a mean of 26 ± 2 and 27 ± 2 mmHg, respectively, indi-
cating that PH was mainly mild to moderate when present.
Baseline demographics, clinical data, and pulmonary func-
tion test were shown in Table 1. Both, COPD and ILD
patients were older than the control group (p < 0.05). The
proportion of women was 5% in COPD, 36% in ILD and
60% in Controls (p < 0.05). However, body mass index was
not different between the groups. The aetiologies of ILD
correspond to Idiopathic Pulmonary Fibrosis (61%); Idio-
pathic non-Specific Interstitial Pneumonitis (10%); Connect-
ive Tissue Disease-related ILD (10%) and others (19%) [24].
Both, functional class and 6MWT showed no differ-
ences between COPD and ILD patients. All patients
showed relative hypoxemia with normo (ILD) or hyper-
capnia (COPD). Both groups showed a severely reduced
FVC, and DLCO had higher impairment in ILD than in
COPD patients (p < 0.05), with out of proportion to the
reduction in lung volume (FVC%/DLCO%). PH patients
walked less than non-PH patients (COPD: 288 ± 28 ver-
sus 307 ± 34 m; and ILD: 280 ± 16 versus 345 ± 22 m),
although only in ILD group reached to statistical signifi-
cance. PH patients presented significant lower partial
Table 1 Demographic, anthropometric, clinical, and pulmonary
function data in control subjects and patients with COPD
and ILD
COPD (n = 18) ILD (n = 28) Control (n = 10)
Age, years 58 ± 1* 58 ± 2* 51 ± 2
Sex, M/F 17/1* 18/10*§ 4/6
BMI, kg/m2 25.0 ± 1.4 26.3 ± 0.8 23.6 ± 1.2
FC II/III/IV, % 0/78/22 14/79/7
6MWT, meters 300 ± 22 315 ± 15
FVC, L 1.8 ± 0.2 1.9 ± 0.14
FVC, % predicted 44 ± 3 50 ± 3
FEV1, L 0.77 ± 0.08 1.56 ± 0.13§
FEV1, % predicted 24 ± 2 58 ± 3§
FEV1/FVC 0.42 ± 0.03 0.82 ± 0.03§
DLCO, % predicted 33 ± 5 27 ± 2§
FVC%/DLCO% 1.5 ± 1.0 2.6 ± 0.3§
PaO2, mm Hg 64 ± 2.3 62 ± 2.4
PaCO2, mm Hg 50 ± 2.3 40 ± 1.4§
Data are mean ± SEM
Abbreviations: BMI body mass index, 6MWT 6-min walking test, DLCO diffusion
capacity of the lung for carbon monoxide, FC functional class, FEV1 forced
expiratory volume in one second, FVC forced vital capacity, PaO2 and PaCO2
partial arterial pressure of oxygen and dioxide of carbon, respectively
*p < 0.05 vs. Control; §p < 0.05 vs. COPD
Table 2 Hemodynamic and IVUS data in control subjects and patients with COPD and ILD with or without pulmonary hypertension
Chronic Obstructive Pulmonary Disease Interstitial Lung Disease Control
All (18) Non PH (10) PH (8) All (28) Non PH (15) PH (13) (10)
mPAP, mm Hg 26 ± 2* 21 ± 1* 33 ± 3*# 27 ± 2* 20 ± 1* 32 ± 3* 15 ± 2
pPAP, mm Hg 16 ± 2* 14 ± 1 18 ± 3* 23 ± 2*§ 17 ± 0.9* 27 ± 4*#§ 11 ± 3
CI, L/min/m2 2.5 ± 0.2 2.3 ± 0.2* 2.5 ± 0.2 2.5 ± 0.1 2.5 ± 0.1 2.5 ± 0.1 2.6 ± 0.1
HR, bpm 76 ± 3 72 ± 4 82 ± 4.4 81 ± 2.6 80 ± 4 83 ± 3 73 ± 1.3
SV, mL 57 ± 2 54 ± 3 56 ± 4 60 ± 2 61 ± 3 59 ± 3 64 ± 2
RAP, mm Hg 8.7 ± 0.7* 7.4 ± 0.7* 10.8 ± 1.2*# 5.4 ± 0.6§ 5.2 ± 0.8 6.1 ± 0.4§ 5.0 ± 1.2
PAWP, mm Hg 10.9 ± 0.7 10.0 ± 1.0 11.6 ± 0.7* 8.0 ± 0.5§ 7.7 ± 0.8 9.0 ± 0.8§ 8.8 ± 0.6
PVR, Wu 3.3 ± 0.3 2.9 ± 1.3 3.9 ± 0.5* 4.1 ± 0.4* 2.9 ± 0.4 5.6 ± 0.4*§# 3.0 ± 0.3
TPR, Wu 6.3 ± 0.6* 5.8 ± 0.6* 7.1 ± 1.1* 6.2 ± 0.5* 4.7 ± 0.4* 8.2 ± 0.6*# 3.3 ± 0.25
Cp, mL/mmHg 4.2 ± 0.28* 4.3 ± 0.3* 3.0 ± 0.7*# 2.9 ± 0.2*§ 3.5 ± 0.2* 2.1 ± 0.1*§ 6.2 ± 0.4
RC time, sec 0.8 ± 0.05* 0.67 ± 0.06* 0.98 ± 0.1*# 0.6 ± 0.02*§ 0.55 ± 0.04* 0.69 ± 0.07*# 1.1 ± 0.03
EM, mm Hg 64 ± 5* 51 ± 5* 79 ± 9*# 105 ± 7*§ 90 ± 7*§ 124 ± 11*§# 21 ± 1.7
AWT, % 23 ± 1* 19 ± 1* 24 ± 1* 17 ± 1*§ 18 ± 1* 15 ± 1 *§# 1.4 ± 1.3
Data are mean ± SEM
Abbreviations: AWT area wall thickness, CI cardiac index, Cp total pulmonary arterial capacitance, EM elastic modulus, HR heart rate, mPAP and pPAP mean and
pulsatile pulmonary arterial pressure, respectively, PAWP pulmonary arterial wedge pressure, PVR pulmonary vascular resistance; SV: stroke volume, RAP right atrial
pressure, TPR total pulmonary resistance
*p < 0.05 vs. Control; §p < 0.05 vs. COPD; #p < 0.05 vs. Non PH
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pressure of arterial oxygen (PaO2) than non-PH patients
(COPD: 59 ± 2 versus 65 ± 2 mmHg; and ILD: 57 ± 2 ver-
sus 66 ± 2 mmHg). Both, FEV1 in COPD patients, and
FVC in ILD patients did not show significant differences
between PH and non-PH patients.
Pulmonary hemodynamics and pulmonary arterial wall
disease in COPD and ILD
ILD patients showed significantly higher pulse PAP
and lower Cp than in COPD patients, in spite of
similar mPAP, which is in relation with a lower RC
time (Table 2).
Figure 1 showed the values of EM and AWT of COPD
and ILD patients, which were significantly higher than
controls, while ILD patients showed a significant higher
EM and lower AWT than COPD patients (p < 0.05). All
except one preLTx COPD patient presented higher EM
(COPD: 22 to 124 mmHg; ILD: 33 to 210 mmHg) and
AWT (COPD: 13 to 34; ILD: 5 to 31) than control sub-
jects (EM: 12 to 30 mmHg and AWT: 1 to 4). Among
the non-PH patients, 7/10 (COPD) and 10/15 (ILD)
patients had a mPAP between 21–24 mmHg.
Figure 2 displays the hyperbolic relationship of TPR
and Cp of both groups, showing that TPR-Cp curve is
shifted downward left for ILD, with a reduced Cp value
for a given TPR. The logarithmically transformed TPR-
Cp plot showed that the slope of the linear regression
for ILD and COPD were −1 and −0.8 respectively, indi-
cating that TPR and Cp are tightly and inversely coupled
in both groups of patients.
Mean diameter of the pulmonary arteries studied was
similar among the different groups (COPD: 1.84 ± 1.3 mm;
ILD: 2.03 ± 1.2 mm; controls: 1.91 ± 1.1 mm).
Relationship between the severity of pulmonary
hemodynamic and pulmonary arterial wall disease
Table 2 summarizes the hemodynamic and IVUS data
for the patients with or without PH. Patients without
PH of both groups showed a significant increased EM
and AWT to control non-PH patients, which is
Fig. 1 Box plots (median and percentiles 25/75) of Elastic Modulus a and area wall thickness b among the different groups. * p < 0.05 vs. Control.
§ p < 0.05 vs. COPD
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associated with a higher mPAP and TPR and lower
Cp and RC time (p < 0.05).
In COPD, both EM (r = 0.66, p < 0.01) and AWT (r = 0.6,
p < 0.05) correlated with mPAP. By contrast, in ILD only
EM (r= 0.63, p < 0.01) worsened with increasing mPAP.
Both, Cp (r = −0.66, p < 0.01) and PVR (r= 0.43, p < 0.05)
were correlated with EM in COPD. On the contrary, in ILD
group, only PVR correlated with EM (r= 0.38, p < 0.05).
Figure 3a and b show the dependence of the Cp and EM to
the working mPAP in both groups. ILD patients showed
lower Cp and higher EM than COPD, either in PH as non-
PH patients.
Relationship between lung function impairment and
pulmonary hemodynamics and arterial wall disease in
COPD and ILD
Both, COPD and ILD patients showed that PaO2 was corre-
lated with mPAP (COPD: r=−0.44, p < 0.01; ILD: r=−0.35,
p < 0.02) and EM (COPD: r=−0.35, p < 0.01; ILD: r=−0.43,
p < 0.01). Only in COPD, partial pressure of carbon dioxide
was correlated with mPAP (r = 0.37) and EM (r = 0.55)
(p < 0.05). Figure 4 showed that only in COPD, EM
and not mPAP, correlated to lung function impair-
ment (FEV1).
Discussion
We analyze the pulmonary vascular disease in candi-
dates for LTx with advanced COPD and ILD. We have
identified several issues having potential clinical rele-
vance: (1) moderate to severe pulmonary vascular
disease is present in almost all patients, even without
PH and is related to hemodynamic severity; (2) patients
with advanced COPD and ILD seem to have different
pulmonary vascular disease; and (3) EM is related to the
severity of airflow limitation in COPD patients.
Pulmonary hemodynamics and pulmonary arterial wall
disease in COPD and ILD patients
In the present cohort of advanced COPD and ILD preLTx
patients, the prevalence of pre-capillary PH was 44% for
COPD and 46% for ILD. This is in agreement with single
center reports and the United Network for Organ Sharing
database [6, 10, 25]. We found 27% of patients with
Fig. 2 a Inverse relationship of Cp-TPR relationship and b Log TPR-log Cp plot. Both curves showed that ILD patients are shifted left downward
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PAWP> 15 mmHg which agrees with the Organ Procure-
ment and Tissue Network (OPTN) database [4].
There are scarce data about the values of EM in
healthy subjects. Sanz et al. estimated the main pulmonary
artery (24–26 mm) stiffness by cardiac magnetic reson-
ance imaging obtaining a median value of 32 mmHg [26].
Very recently, Shen et al. using IVUS imaging, assessed
the EM of elastic pulmonary arteries of 4.4 ± 0.2 mm,
obtaining a mean value of 44 ± 4 mmHg [27]. Both, age
and range of mPAP of control patients are similar among
the studies, excepting the control group of Shen’s work
that included patients with connective tissue disease with-
out PH, which can explain the higher values of EM sec-
ondary to some degree of subclinical vascular remodeling.
One of the main findings of the present study is the
observation that patients without PH presented a signifi-
cant pulmonary vascular disease with respect to controls.
The increase of EM and AWT may indicate an early and
significant pulmonary vascular disease in non-PH-lung
disease patients. Therefore, the rise in resting mPAP above
25 mmHg is a late marker of the pulmonary vascular
disease process [28]. Unlike several studies that attempt to
detect some degree of pulmonary vascular disease through
the exercise hemodynamic impairment [25, 29, 30], our
results raise the assessment of PA wall behavior as an
alternative tool to make the diagnosis of vasculopathy at a
preclinical stage [31].
COPD patients showed a lower EM and higher Cp
than ILD beyond mPAP; that was associated with a more
preserved RC time and a right upward RC plot, such
that Cp was higher for a given TPR. We analyzed the
relationship between TPR and Cp and not PVR-Cp, to
avoid the potential risk of misleading PAWP measure-
ments [32, 33]. Probably the higher collagen fibers con-
tent of the arterial wall associated with the lung tissue
fibrotic process could explain the greater stiffness with
less thickness of the wall of ILD patients. This is in
agreement with Hoffmann et al. [34] who have recently
Fig. 3 a Correlation between total pulmonary arterial capacitance (Cp) and mean pulmonary arterial pressure (mPAP) in COPD and ILD patients and
b Correlation between elastic modulus (EM) and mPAP in COPD and ILD patients. The dotted line indicates the threshold for PH (mPAP = 25 mm Hg).
The gray rectangle indicates mPAP between 21–24 mm Hg. CTL Controls
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reported that pulmonary arterial remodeling in PH-
COPD and PH-IPF patients is caused by different
molecular mechanisms.
The higher RAP and PAWP of COPD than ILD
patients could be related to a higher end-expiration
intrathoracic pressure [35].
Relationship between pulmonary arterial wall disease and
lung function impairment in COPD and ILD
Multiple mechanisms have been postulated as under-
lying the development of PH in COPD but remain
incompletely understood [36]. Both hypoxemia and
hypercapnia showed a significant correlation with mPAP
and EM in our pre-LTx COPD patients. Each one
explains about 15 to 30% of mPAP and EM variation,
reflecting the important role of chronic hypoxia and
hypercapnia in vascular disease. The absence of correlation
between the AWT and mPAP is in accordance to Kubo
et al. [37], which reported that in contrast to mPAP at rest,
mPAP during exercise was strongly related to pulmonary
arterial wall thickness. Finally, the absence or weak cor-
relation between PH and airway obstruction has been
widely known and fits with our results [29, 38]. How-
ever, we obtained a strong relationship between FEV1
and EM (r = −0.55), highlighting that airflow limitation
may be related to the severity of vasculopathy.
The pathogenesis of PH in ILD is also complex and
multifactorial [39]. Correlations between PaO2 and
mPAP and EM in the present study, illustrate the
importance of hypoxia in vascular disease. The loss of
pulmonary vasculature has been challenged as the main
factor for the development of PH in ILD, especially in
IPF [40]. Accordingly, previous and current studies did
not show a positive relationship between the degree of
restrictive physiology and PH [7, 10].
Regarding clinical differences, only ILD patients with
PH have shown a 6MWT significantly lower than
patients without PH, which may be related to the more
severe wall remodeling.
Study limitations
We measured intravascular pulmonary pressures at the end
of expiration to minimize the effect of intrathoracic pres-
sure changes during the respiratory cycle since the intra
and extrathoracic pressures are equal (pleural pressure is
closest to 0 = atmospheric pressure) and so, intravascular
and transmural pressures are similar. Respiratory swings
are usually more pronounced in advanced COPD patients,
so, intrathoracic pressure is increased during expiration
and may be greater than atmospheric pressure. Although
averaging intravascular pulmonary pressures over the
respiratory cycle may be better estimates of transmural
Fig. 4 Correlations between lung function and Elastic Modulus and mean pulmonary arterial pressure (mPAP) of COPD (% of FEV1 predicted)
and ILD (% of FVC predicted) patients
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pressures, particularly, during exercise in COPD patients
[35], we employed end-expiratory measurements based on
the recommendations for resting measurements [17]. We
cannot discard an expiratory increase of RAP and PAWP
that may explain the significantly higher values of the
COPD patients [41]. Concomitantly, the pulse PAP and
mPAP may decrease during spontaneous expiration in
COPD patients at rest [42]. Therefore, we were careful to
analyze the Cp (SV/pulse PAP) and EM (pulse PAP/
IVUSp) for a given mPAP. This allowed to find out there
are real differences in pulmonary vascular disease between
COPD and ILD.
Although the non-PH control patients were not age- and
sex-matched to COPD and ILD patients, age-related pul-
monary arterial stiffness begins after ~ 50 years old [43].
We evaluate pre-LTx COPD and ILD patients, there-
fore, our findings cannot apply to all population of
COPD and ILD. They also need external validity, since
the present study shows the assessment of 46 patients
from a single center.
Although the pathologic manifestations of each of the
ILDs and their distribution within the lung parenchyma
play a role in determining concomitant PH, more than half
of PH-ILD patients included corresponding to IPF [8].
The absence of a significant correlation between the
EM and the percentage of FVC predicted would allow
discarding a prevail effect of the different perivascular
pressures exerted by lung tissue connections on the elas-
tic properties of the pulmonary arteries in ILD patients.
Conclusions
The present study shows that PH is a late marker of the
pulmonary vascular disease process in COPD and ILD
candidates for LTx. PA stiffness (assesses by the EM)
and the relative area of wall thickness can make the
diagnosis of pulmonary vasculopathy at a preclinical
stage. Patients with advanced COPD and ILD appear to
have a different pulmonary vascular disease. ILD patients
showed a worse pulmonary vascular disease with higher
EM and lower Cp for a given mPAP. Airflow limitations
in COPD but not restriction impairment in ILD patients
would be associated with the pulmonary vascular
disease. Further research is needed to identify optimal
screening methods for pulmonary vascular disease in
this patient population and to explore specific thera-
peutic options.
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